Ultragenyx Pharmaceutical (RARE) EBITDA (2013 - 2026)
Ultragenyx Pharmaceutical's EBITDA was -$67 million in Q2 2026, compared with -$99 million a year earlier.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) EBITDA (2013 - 2026) Analysis & Trends
On a trailing twelve-month basis, Ultragenyx Pharmaceutical's EBITDA was -$495.17 million through Jun 30, 2026; for FY2025, it came in at -$500 million.
- In earlier years, EBITDA was -$500 million in FY2024, -$543 million in FY2023, -$630.7 million in FY2022 and -$368.5 million in FY2021.
- The Q2 2026 figure marks the highest quarterly EBITDA since Q3 2020.
- Per Business Quant data, RARE's EBITDA in the three quarters before Q2 2026 was -$161 million (Q1 2026), -$104.5 million (Q4 2025) and -$162.68 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 9.10 Bn |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | 8.33 Bn |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | 999.00 Mn |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | 5.09 Bn |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 4.63 Bn |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | -9.70 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 5.89 Bn |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 1.30 Bn |
| 10 | Ultragenyx Pharmaceutical | 1.51 Bn | -292.70 Mn | 180.00 Mn | -67.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -67.00 Mn |
| Mar 31, 2026 | -161.00 Mn |
| Dec 31, 2025 | -104.50 Mn |
| Sep 30, 2025 | -162.68 Mn |
| Jun 30, 2025 | -99.00 Mn |
| Mar 31, 2025 | -134.00 Mn |
| Dec 31, 2024 | -112.77 Mn |
| Sep 30, 2024 | -123.23 Mn |
| Jun 30, 2024 | -107.50 Mn |
| Mar 31, 2024 | -156.50 Mn |
| Dec 31, 2023 | -113.63 Mn |
| Sep 30, 2023 | -137.91 Mn |
| Jun 30, 2023 | -142.60 Mn |
| Mar 31, 2023 | -148.87 Mn |
| Dec 31, 2022 | -140.67 Mn |
| Sep 30, 2022 | -220.37 Mn |
| Jun 30, 2022 | -137.11 Mn |
| Mar 31, 2022 | -132.54 Mn |
| Dec 31, 2021 | -99.03 Mn |
| Sep 30, 2021 | -86.61 Mn |
API Access
Ultragenyx Pharmaceutical EBITDA API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda&ticker=RARE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda", "ticker": "RARE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda&ticker=RARE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();